Boston, November 10, 2025 — Rhythm Pharmaceuticals, Inc. has announced the presentation of four pivotal datasets at ObesityWeek® 2025, advancing the scientific and clinical understanding of its precision obesity therapy setmelanotide. The findings provide new evidence for the drug’s efficacy, safety, and patient impact in acquired hypothalamic obesity, a severe and rare metabolic disorder driven by neuroendocrine dysfunction.

Science Significance

The four datasets represent an extensive body of evidence demonstrating that setmelanotide, an MC4R (melanocortin-4 receptor) agonist, can significantly improve weight outcomes and hunger regulation among patients whose obesity results from hypothalamic injury or dysfunction. The headline findings from the Phase 3 TRANSCEND clinical trial showed that patients receiving setmelanotide achieved an average placebo-adjusted BMI reduction of 19% (p < 0.0001) over 52 weeks. Among participants who concurrently used GLP-1 receptor agonists, such as semaglutide, an even greater BMI reduction of 27.1% was observed. These results demonstrate a potentially additive or synergistic effect between setmelanotide and other metabolic therapies. In addition to efficacy data, Rhythm presented new patient-reported outcomes highlighting significant reductions in hunger, improved energy levels, and enhanced quality of life. Notably, in younger populations, improvements in physical activity and emotional well-being were also reported. These findings validate the drug’s mechanism as more than a metabolic intervention — it appears to directly affect neurobehavioral aspects of appetite and motivation.

Regulatory Significance

The U.S. Food and Drug Administration (FDA) has accepted Rhythm’s supplemental New Drug Application (sNDA) for setmelanotide with Priority Review status. A PDUFA decision date of December 20, 2025 has been set. The new datasets reinforce the company’s regulatory position by offering additional long-term safety data, efficacy evidence across sub-populations, and real-world patient experience outcomes. These expanded datasets could support label expansion for setmelanotide, enabling its approval for acquired hypothalamic obesity — in addition to previously approved indications for rare genetic obesity syndromes such as POMC, LEPR, and Bardet-Biedl Syndrome. For Rhythm, this represents a pathway to broaden the therapeutic reach of its core asset into new rare-disease territories.

Business Significance

From a commercial perspective, Rhythm’s growing clinical validation positions it strongly in a rapidly expanding global obesity market, which analysts estimate will exceed $150 billion by 2030. Unlike broader obesity drugs focused on lifestyle-related weight gain, Rhythm’s therapy targets a defined rare-disease population, supporting premium pricing and orphan-drug advantages such as market exclusivity and tax incentives.The strong GLP-1 combination data may open additional partnership opportunities with companies developing incretin-based agents. Such collaborations could extend setmelanotide’s utility into broader obesity subtypes or combination therapies for metabolic disorders.

Patients’ Significance

Patients living with acquired hypothalamic obesity (AHO) often experience extreme and uncontrollable hunger, rapid weight gain, and severe metabolic complications following hypothalamic injury due to tumors, trauma, or surgery. Currently, there are no approved therapies specifically indicated for this condition. Setmelanotide’s demonstrated ability to reduce hunger and promote clinically meaningful weight loss offers a first-in-class therapeutic option. Beyond numerical weight reduction, patients in the study reported enhanced psychological well-being, improved energy levels, and greater social functioning — outcomes that resonate deeply within quality-of-life metrics.

Policy Significance

Globally, the recognition of obesity as a chronic disease rather than a lifestyle issue is transforming healthcare policy. Precision medicines like setmelanotide could influence reimbursement models, encourage inclusion in rare-disease registries, and justify insurance coverage for neuroendocrine obesity conditions. Furthermore, the research underlines the importance of incorporating patient-reported outcomes (PROs) into regulatory and policy evaluation frameworks. Health authorities may increasingly rely on PROs as evidence of real-world benefit, complementing traditional endpoints like BMI or HbA1c.

The presentation of four new datasets at ObesityWeek® 2025 marks a defining milestone in Rhythm Pharmaceuticals’ mission to redefine obesity treatment through molecular precision. As the company approaches its FDA decision date, the strength of its scientific, regulatory, and patient-centric evidence positions setmelanotide as a transformative therapy for individuals with acquired hypothalamic obesity. With its compelling blend of robust science, regulatory readiness, and real-world relevance, Rhythm Pharmaceuticals continues to illuminate the path toward a new era of biologically tailored obesity care.

Source: Rhythm Pharmaceuticals, Inc. press release